The authors examined a group of 30 young people aged 19-23 years who suffered from chronic algic dyspeptic complaints of the upper type persisting for 3-36 months. The prerequisite for inclusion into the group were normal results of endoscopy, the physical finding and standard biochemical examinations. In all these patients dynamic scintigraphy of the oesophagus was made. A quite normal finding was recorded only in three patients (10%). In the remaining 27 (90%) major or minor abnormalities were recorded. This is in marked contrast with the results of dynamic scintigraphy of the oesophagus in 19 healthy volunteers of the same age. In the latter a normal finding was obtained in 15 (79%) and deviations from it only in four subjects (21%). Dynamic scintigraphy of the oesophagus is a simple easily performed method which in a selected group of patients has become an objective criterion of their chronic complaints.

Download full-text PDF

Source

Publication Analysis

Top Keywords

dynamic scintigraphy
12
scintigraphy oesophagus
12
normal finding
8
[dynamic scintigraphy
4
scintigraphy esophagus
4
esophagus young
4
young persons
4
persons functional
4
functional algesic-dyspeptic
4
algesic-dyspeptic disorders
4

Similar Publications

Background: Reactive astrogliosis refers to functional and morphological changes in astrocytes that occur with neuronal damage in numerous neurological conditions. PET tracers targeting monoamine oxidase B (MAO-B) are used to visualize reactive astrogliosis in the living brain. [F]SMBT-1, a MAO-B selective PET tracer, was developed by modifying the chemical structure of [F]THK5351.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

BC Neuroimmunology lab, Vancouver, BC, Canada.

Background: Blood-based biomarkers will be essential for providing clinicians an accessible and cost-effective Alzheimer's disease (AD) screening tool. Elevated levels of two phosphorylated tau biomarkers (pTau181 & pTau217) correlated with amyloid and tau-PET consistent with AD diagnosis. We evaluated the analytical and clinical performance of each biomarkers using two different high-sensitivity methodologies (CLEIA and Simoa®) in a single laboratory to compare the performance of pTau181 and 217 in a clinical (CLIA-certified) laboratory.

View Article and Find Full Text PDF

Background: The modelling of biomarker dynamics in Alzheimer's Disease from cohort studies faces challenges due to the lack of clear temporal points of references and the natural variability across individuals. Mixed-effects models are often used to account for individual differences, but a disease timescale can enable better population-level modelling than age or time since enrolment. Previous literature explored the temporal synchronisation of patients through observed time of conversion to MCI or AD, amyloid positivity, or aligning cognitive trajectories.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Alzheimer Research Centre, Leuven Brain Institute, KU Leuven, Leuven, Belgium.

Background: The performance of blood-based phosphorylated tau (pTau) immunoassays to detect asymptomatic Alzheimer's disease (AD) has important implications for therapeutic trials. pTau217 is often recommended as the preferred epitope due to its high fold changes in AD. The current study investigates the ability of a novel pTau217 assay to predict the dynamic phase of amyloid-β (Aβ) accumulation in comparison to the best-performing pTau181 assay.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Lawrence Berkeley National Laboratory, Berkeley, CA, USA.

Background: Differences between on- and off-target retention characteristics between [F]MK6240 and [F]Flortaucipir (FTP) complicate the harmonization across tracers. Our objective here was to separate the impact of the reference region by evaluating correlations between [F]MK6240 (MK) and [F]FTP standard uptake values (SUVs).

Method: Participants (Figure 1, n=90) received an amyloid-β (Aβ) PET scan ([C]PIB or [F]NAV4694) and two tau-PET scans: [F]MK (90-110 minutes post-injection) and [F]FTP (80-100 minutes post-injection).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!